{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:03:06Z","timestamp":1793901786594,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00417-025-06820-x","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:57:57Z","timestamp":1743814677000},"page":"2177-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Persistent avascular retina in retinopathy of prematurity"],"prefix":"10.1007","volume":"263","author":[{"given":"Ting Fang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ann","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Agarwal-Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Siew Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-3597","authenticated-orcid":false,"given":"Andrew S. H.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"6820_CR1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O (2013) Retinopathy of prematurity. Lancet 382:1445\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(13)60178-6","journal-title":"Lancet"},{"key":"6820_CR2","doi-asserted-by":"publisher","first-page":"e002267","DOI":"10.1136\/bmjpo-2023-002267","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Liu J, Zhang X et al (2024) Global, regional and national burden of retinopathy of prematurity among childhood and adolescent: a spatiotemporal analysis based on the Global Burden of Disease Study 2019. BMJ Paediatrics Open 8:e002267. https:\/\/doi.org\/10.1136\/bmjpo-2023-002267","journal-title":"BMJ Paediatrics Open"},{"issue":"3","key":"6820_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3345\/cep.2021.00773","volume":"65","author":"EH Hong","year":"2022","unstructured":"Hong EH, Shin YU, Cho H (2022) Retinopathy of prematurity: a review of epidemiology and current treatment strategies. Clin Exp Pediatr 65(3):115\u2013126. https:\/\/doi.org\/10.3345\/cep.2021.00773","journal-title":"Clin Exp Pediatr"},{"issue":"10","key":"6820_CR4","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR et al (2021) International classification of retinopathy of prematurity Third Edition. Ophthalmology 128(10):e51\u2013e68. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.031","journal-title":"Ophthalmology"},{"key":"6820_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"W Tasman","year":"1988","unstructured":"Tasman W (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 106:463\u20134. https:\/\/doi.org\/10.1001\/archopht.1988.01060130517027","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"6820_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684\u201394. https:\/\/doi.org\/10.1001\/archopht.121.12.1684","journal-title":"Arch Ophthalmol"},{"key":"6820_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s40746-022-00249-8","volume":"8","author":"ASH Tsai","year":"2022","unstructured":"Tsai ASH, Acaba-Berrocal L, Sobhy M et al (2022) Current Management of Retinopathy of Prematurity. Curr Treat Options Peds 8:246\u2013261. https:\/\/doi.org\/10.1007\/s40746-022-00249-8","journal-title":"Curr Treat Options Peds"},{"issue":"1","key":"6820_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","volume":"18","author":"Z Li","year":"2018","unstructured":"Li Z, Zhang Y, Liao Y et al (2018) Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol 18(1):19. https:\/\/doi.org\/10.1186\/s12886-018-0685-6","journal-title":"BMC Ophthalmol"},{"key":"6820_CR9","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","volume":"88","author":"AS Tsai","year":"2022","unstructured":"Tsai AS, Chou HD, Ling XC et al (2022) Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res 88:101018. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.101018","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"6820_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4274\/tjo.galenos.2022.76436","volume":"53","author":"\u015e \u00d6zdek","year":"2023","unstructured":"\u00d6zdek \u015e, \u00d6zdemirZeydanl\u0131 E, Baumal C et al (2023) Avascular Peripheral Retina in Infants. Turk J Ophthalmol 53(1):44\u201357. https:\/\/doi.org\/10.4274\/tjo.galenos.2022.76436","journal-title":"Turk J Ophthalmol"},{"issue":"3","key":"6820_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157.PMID:22681939;PMCID:PMC3756139","volume":"16","author":"MP Blair","year":"2012","unstructured":"Blair MP, Shapiro MJ, Hartnett ME (2012) Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. J AAPOS 16(3):234\u20137. https:\/\/doi.org\/10.1016\/j.jaapos.2011.12.157.PMID:22681939;PMCID:PMC3756139","journal-title":"J AAPOS"},{"issue":"10","key":"6820_CR12","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","volume":"123","author":"BC Toy","year":"2016","unstructured":"Toy BC, Schachar IH, Tan GS, Moshfeghi DM (2016) Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity. Ophthalmology 123(10):2166\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2016.06.055","journal-title":"Ophthalmology"},{"issue":"7","key":"6820_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/IAE.0b013e31820d3f70","volume":"31","author":"LY Ho","year":"2011","unstructured":"Ho LY, Ho V, Aggarwal H et al (2011) Management of avascular peripheral retina in older prematurely born infants. Retina 31(7):1248\u201354. https:\/\/doi.org\/10.1097\/IAE.0b013e31820d3f70","journal-title":"Retina"},{"issue":"2","key":"6820_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.oret.2023.10.004","volume":"8","author":"TB de Oliveira","year":"2024","unstructured":"de Oliveira TB, Young BK, Ostmo SR et al (2024) Macular thickness is associated with persistent avascular retina in patients with a history of untreated retinopathy of prematurity. Ophthalmol Retina 8(2):202\u2013204. https:\/\/doi.org\/10.1016\/j.oret.2023.10.004","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"6820_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/s0161-6420(94)31301-7","volume":"101","author":"HA Mintz-Hittner","year":"1994","unstructured":"Mintz-Hittner HA, Kretzer FL (1994) Postnatal retinal vascularization in former preterm infants with retinopathy of prematurity. Ophthalmology 101(3):548\u201358. https:\/\/doi.org\/10.1016\/s0161-6420(94)31301-7","journal-title":"Ophthalmology"},{"issue":"6","key":"6820_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28(6):831\u20138. https:\/\/doi.org\/10.1097\/IAE.0b013e318177f934","journal-title":"Retina"},{"issue":"7","key":"6820_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"6","key":"6820_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jop.2011.0060","volume":"27","author":"BC Harder","year":"2011","unstructured":"Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC (2011) Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 27(6):623\u20137. https:\/\/doi.org\/10.1089\/jop.2011.0060","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"6820_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98(4):507\u201312. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304109","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"6820_CR20","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M et al (2016) Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol 94(6):e417-20. https:\/\/doi.org\/10.1111\/aos.13008","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"6820_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00417-019-04292-4","volume":"257","author":"I Perente","year":"2019","unstructured":"Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: Late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257(6):1141\u20131146. https:\/\/doi.org\/10.1007\/s00417-019-04292-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"6820_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","volume":"2","author":"O Ar\u00e1mbulo","year":"2018","unstructured":"Ar\u00e1mbulo O, Dib G, Iturralde J, Brito M, Fortes Filho J (2018) Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity. Ophthalmol Retina 2(8):858\u2013863. https:\/\/doi.org\/10.1016\/j.oret.2017.11.012","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"6820_CR23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.18240\/ijo.2019.07.15","volume":"12","author":"QY Meng","year":"2019","unstructured":"Meng QY, Cheng Y, Zhao MW, Liang JH (2019) The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China. Int J Ophthalmol. 12(7):1146\u20131150. https:\/\/doi.org\/10.18240\/ijo.2019.07.15","journal-title":"Int J Ophthalmol."},{"issue":"1","key":"6820_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.18240\/ijo.2019.01.12","volume":"12","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Liu TG, Li WY, Zhao MW, Liang JH (2019) Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity. Int J Ophthalmol 12(1):79\u201382. https:\/\/doi.org\/10.18240\/ijo.2019.01.12","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"6820_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40942-022-00402-3","volume":"8","author":"R Al Rasheed","year":"2022","unstructured":"Al Rasheed R, Adhi MI, Alowedi SA, Albdah B, Aldebasi T, Hazzazi MA (2022) Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography. Int J Retina Vitreous 8(1):53. https:\/\/doi.org\/10.1186\/s40942-022-00402-3","journal-title":"Int J Retina Vitreous"},{"issue":"3","key":"6820_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyama\u00e7Sukgen","year":"2016","unstructured":"Alyama\u00e7Sukgen E, \u00c7\u00f6mez A, Ko\u00e7luk Y, Cevher S (2016) The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab. Ophthalmologica 236(3):139\u2013147. https:\/\/doi.org\/10.1159\/000449530","journal-title":"Ophthalmologica"},{"issue":"3","key":"6820_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang CY, Lien R, Wang NK et al (2018) Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 256(3):479\u2013487. https:\/\/doi.org\/10.1007\/s00417-017-3878-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"6820_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","volume":"67","author":"V Vedantham","year":"2019","unstructured":"Vedantham V (2019) Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity. Indian J Ophthalmol 67(6):884\u2013888. https:\/\/doi.org\/10.4103\/ijo.IJO_708_18","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"6820_CR29","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.14460","volume":"98","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J (2020) Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol 98(8):e1004\u2013e1008. https:\/\/doi.org\/10.1111\/aos.14460","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"6820_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3341\/kjo.2018.0011","volume":"32","author":"HG Kang","year":"2018","unstructured":"Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, Kim M (2018) Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: Efficacy, safety, and anatomical outcomes. Korean J Ophthalmol 32(6):451\u2013458. https:\/\/doi.org\/10.3341\/kjo.2018.0011","journal-title":"Korean J Ophthalmol"},{"issue":"4","key":"6820_CR31","doi-asserted-by":"publisher","first-page":"e248383","DOI":"10.1001\/jamanetworkopen.2024.8383","volume":"7","author":"A Stahl","year":"2024","unstructured":"Stahl A, Nakanishi H, Lepore D et al (2024) FIREFLEYE next study group. Intravitreal aflibercept vs laser therapy for retinopathy of prematurity: Two-year efficacy and safety outcomes in the nonrandomized controlled trial FIREFLEYE next. JAMA Netw Open 7(4):e248383. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.8383","journal-title":"JAMA Netw Open"},{"issue":"12","key":"6820_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3928\/23258160-20211124-01","volume":"52","author":"PJ Chen","year":"2021","unstructured":"Chen PJ, Rossin EJ, Vavvas DG (2021) Aflibercept for retinopathy of prematurity: A systematic review and meta-analysis. Ophthalmic Surg Lasers Imaging Retina 52(12):673\u2013681. https:\/\/doi.org\/10.3928\/23258160-20211124-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"6820_CR33","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1038\/s41598-018-28987-6","volume":"8","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Meng Q, Linghu D et al (2018) A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity. Sci Rep 8(1):10732. https:\/\/doi.org\/10.1038\/s41598-018-28987-6","journal-title":"Sci Rep"},{"issue":"8","key":"6820_CR34","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","volume":"38","author":"E Jin","year":"2018","unstructured":"Jin E, Yin H, Li X, Zhao M (2018) Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity. Retina 38(8):1595\u20131604. https:\/\/doi.org\/10.1097\/IAE.0000000000001763","journal-title":"Retina"},{"issue":"4","key":"6820_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","volume":"103","author":"Y Bai","year":"2019","unstructured":"Bai Y, Nie H, Wei S et al (2019) Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol 103(4):494\u2013498. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311662","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"6820_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12887-024-05017-1.PMID:39215256;PMCID:PMC11363585","volume":"24","author":"XM Yang","year":"2024","unstructured":"Yang XM, Li QP, Wang ZH, Zhang MN (2024) Comparison of ranibizumab and conbercept treatment in type 1 prethreshold retinopathy of prematurity in zone II. BMC Pediatr. 24(1):556. https:\/\/doi.org\/10.1186\/s12887-024-05017-1.PMID:39215256;PMCID:PMC11363585","journal-title":"BMC Pediatr."},{"issue":"4","key":"6820_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3980\/j.issn.2222-3959.2013.04.13","volume":"6","author":"RH Ju","year":"2013","unstructured":"Ju RH, Zhang JQ, Ke XY, Lu XH, Liang LF, Wang WJ (2013) Spontaneous regression of retinopathy of prematurity: incidence and predictive factors. Int J Ophthalmol 6(4):475\u201380. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2013.04.13","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"6820_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaapos.2021.09.004","volume":"26","author":"AM Hanif","year":"2022","unstructured":"Hanif AM, Gensure RH, Scruggs BA et al (2022) Prevalence of persistent avascular retina in untreated children with a history of retinopathy of prematurity screening. J AAPOS 26(1):29\u201331. https:\/\/doi.org\/10.1016\/j.jaapos.2021.09.004","journal-title":"J AAPOS"},{"issue":"4","key":"6820_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3928\/01913913-20190501-01","volume":"56","author":"R Al-Taie","year":"2019","unstructured":"Al-Taie R, Simkin SK, Dou\u00e7et E, Dai S (2019) Persistent avascular retina in infants with a history of type 2 retinopathy of prematurity: To treat or not to treat? J Pediatr Ophthalmol Strabismus 56(4):222\u2013228. https:\/\/doi.org\/10.3928\/01913913-20190501-01","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"6","key":"6820_CR40","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","volume":"4","author":"AE Hamad","year":"2020","unstructured":"Hamad AE, Moinuddin O, Blair MP et al (2020) Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol Retina 4(6):602\u2013612. https:\/\/doi.org\/10.1016\/j.oret.2019.12.015","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"6820_CR41","doi-asserted-by":"publisher","first-page":"100281","DOI":"10.1016\/j.xops.2023.100281","volume":"3","author":"XC Ling","year":"2023","unstructured":"Ling XC, Kang EY, Huang JL et al (2023) Persistent Vascular Anomalies in Retinopathy of Prematurity Children: Ultrawide-field Fluorescein Angiography Findings until School Age. Ophthalmol Sci 3(3):100281. https:\/\/doi.org\/10.1016\/j.xops.2023.100281","journal-title":"Ophthalmol Sci"},{"key":"6820_CR42","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV (2004) Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233\u201348","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"8","key":"6820_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3928\/23258160-20180803-11","volume":"49","author":"L Golas","year":"2018","unstructured":"Golas L, Shapiro MJ, Blair MP (2018) Late ROP reactivation and retinal detachment in a teenager. Ophthalmic Surg Lasers Imaging Retina 49(8):625\u2013628. https:\/\/doi.org\/10.3928\/23258160-20180803-11","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6820_CR44","doi-asserted-by":"publisher","unstructured":"Fierson WM (2018) American Academy Of Pediatrics Section on Ophthalmology; American Academy Of Ophthalmology; American Association For Pediatric Ophthalmology And Strabismus; American Association Of Certified Orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics 142(6):e20183061. https:\/\/doi.org\/10.1542\/peds.2018-3061. Erratum in (2019) Pediatrics 143(3):e20183810. https:\/\/doi.org\/10.1542\/peds.2018-3810.","DOI":"10.1542\/peds.2018-3061"},{"issue":"10","key":"6820_CR45","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10792-018-01064-7","volume":"39","author":"A Vural","year":"2019","unstructured":"Vural A, Ekinci DY, Onur IU, Herg\u00fcnsel GO, Yi\u011fit FU (2019) Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. Int Ophthalmol 39(10):2267\u20132274. https:\/\/doi.org\/10.1007\/s10792-018-01064-7","journal-title":"Int Ophthalmol"},{"issue":"1","key":"6820_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clinthera.2022.12.003","volume":"45","author":"JD Hammer","year":"2023","unstructured":"Hammer JD, Nguyen H, Palmer J, Furtney S, Agarwal-Sinha S (2023) Computed analysis of retinal vascular growth after bevacizumab treatment of retinopathy of prematurity until age 3 years. Clin Ther. 45(1):4\u201316. https:\/\/doi.org\/10.1016\/j.clinthera.2022.12.003","journal-title":"Clin Ther."},{"issue":"9","key":"6820_CR47","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. Ophthalmology 123(9):1845\u201355. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"issue":"3","key":"6820_CR48","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","volume":"58","author":"J Lyu","year":"2017","unstructured":"Lyu J, Zhang Q, Chen CL et al (2017) Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: Timing and risk factors. Invest Ophthalmol Vis Sci 58(3):1719\u20131725. https:\/\/doi.org\/10.1167\/iovs.16-20680","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"6820_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/ICB.0b013e318285238e","volume":"7","author":"S Mehta","year":"2013","unstructured":"Mehta S, Hubbard GB 3rd (2013) Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity. Retin Cases Brief Rep 7(3):206\u20139. https:\/\/doi.org\/10.1097\/ICB.0b013e318285238e","journal-title":"Retin Cases Brief Rep"},{"issue":"8","key":"6820_CR50","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ophtha.2015.04.023","volume":"122","author":"MA Klufas","year":"2015","unstructured":"Klufas MA, Patel SN, Ryan MC et al (2015) Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity. Ophthalmology 122(8):1601\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.023","journal-title":"Ophthalmology"},{"issue":"Suppl 3","key":"6820_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/14767058.2012.712313","volume":"25","author":"V Purcaro","year":"2012","unstructured":"Purcaro V, Baldascino A, Papacci P et al (2012) Fluorescein angiography and retinal vascular development in premature infants. J Matern Fetal Neonatal Med 25(Suppl 3):53\u20136. https:\/\/doi.org\/10.3109\/14767058.2012.712313","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"Suppl 1","key":"6820_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40942-019-0171-1","volume":"5","author":"N Kothari","year":"2019","unstructured":"Kothari N, Pineles S, Sarraf D et al (2019) Clinic-based ultra-wide field retinal imaging in a pediatric population. Int J Retina Vitreous 5(Suppl 1):21. https:\/\/doi.org\/10.1186\/s40942-019-0171-1","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"6820_CR53","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4103\/ijo.IJO_1917_20","volume":"69","author":"K Agarwal","year":"2021","unstructured":"Agarwal K, Vinekar A, Chandra P et al (2021) Imaging the pediatric retina: An overview. Indian J Ophthalmol 69(4):812\u2013823. https:\/\/doi.org\/10.4103\/ijo.IJO_1917_20","journal-title":"Indian J Ophthalmol"},{"key":"6820_CR54","unstructured":"Susmito B,\u00a0Jane G,\u00a0Paulo E S (2012) Optos\u00ae Widefield Retinal Imaging in a Paediatric Vitreoretinal Service.\u00a0Invest Ophthalmol Vis Sci 53(14):1164. Available from: https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2350550."},{"issue":"5","key":"6820_CR55","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","volume":"3","author":"SA Mansukhani","year":"2019","unstructured":"Mansukhani SA, Hutchinson AK, Neustein R et al (2019) Fluorescein angiography in retinopathy of prematurity: Comparison of infants treated with bevacizumab to those with spontaneous regression. Ophthalmol Retina 3(5):436\u2013443. https:\/\/doi.org\/10.1016\/j.oret.2019.01.016","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"6820_CR56","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaophthalmol.2019.2442","volume":"137","author":"K Gupta","year":"2019","unstructured":"Gupta K, Campbell JP, Taylor S et al (2019) Imaging and informatics in retinopathy of prematurity consortium. A quantitative severity scale for retinopathy of prematurity using deep learning to monitor disease regression after treatment. JAMA Ophthalmol 137(9):1029\u20131036. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.2442","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"6820_CR57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2023.09.032","volume":"131","author":"H Robles-Holmes","year":"2024","unstructured":"Robles-Holmes H, Coyner AS, Campbell JP, Nudleman E (2024) Imaging features associated with persistent avascular retina in retinopathy of prematurity. Ophthalmology 131(1):122\u2013124. https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.032","journal-title":"Ophthalmology"},{"issue":"4","key":"6820_CR58","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M (2018) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38(4):764\u2013772. https:\/\/doi.org\/10.1097\/IAE.0000000000001581","journal-title":"Retina"},{"key":"6820_CR59","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/s0161-6420(01)00660-1","volume":"108","author":"RS Kaiser","year":"2001","unstructured":"Kaiser RS, Trese MT, Williams GA, Cox MS Jr (2001) Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology 108:1647\u20131653. https:\/\/doi.org\/10.1016\/s0161-6420(01)00660-1","journal-title":"Ophthalmology"},{"key":"6820_CR60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ajo.2007.11.007","volume":"145","author":"RS Kaiser","year":"2008","unstructured":"Kaiser RS, Fenton GL, Tasman W, Trese MT (2008) Adult retinopathy of prematurity: retinal complications from cataract surgery. Am J Ophthalmol 145:729\u2013735. https:\/\/doi.org\/10.1016\/j.ajo.2007.11.007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"6820_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jcjo.2020.05.017","volume":"55","author":"A Gonzalez","year":"2020","unstructured":"Gonzalez A, Agarwal-Sinha S (2020) Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina. Can J Ophthalmol 55(5):373\u2013381. https:\/\/doi.org\/10.1016\/j.jcjo.2020.05.017","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"6820_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13063-020-04371-6","volume":"21","author":"Y Yu","year":"2020","unstructured":"Yu Y, Wang J, Chen F, Chen W, Jiang N, Xiang D (2020) Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity. Trials 21(1):493. https:\/\/doi.org\/10.1186\/s13063-020-04371-6","journal-title":"Trials"},{"issue":"1","key":"6820_CR63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.oret.2022.07.005","volume":"7","author":"HT Hsu","year":"2023","unstructured":"Hsu HT, Yu-Chuan Kang E, Blair MP et al (2023) Late vitreoretinal complications of regressed retinopathy of prematurity: Retinal break, vitreous hemorrhage, and retinal detachment. Ophthalmol Retina 7(1):72\u201380. https:\/\/doi.org\/10.1016\/j.oret.2022.07.005","journal-title":"Ophthalmol Retina"},{"key":"6820_CR64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2021.07.016","volume":"233","author":"AM Berrocal","year":"2022","unstructured":"Berrocal AM, Fan KC, Al-Khersan H, Negron CI, Murray T (2022) Retinopathy of prematurity: Advances in the screening and treatment of retinopathy of prematurity using a single center approach. Am J Ophthalmol 233:189\u2013215. https:\/\/doi.org\/10.1016\/j.ajo.2021.07.016","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6820_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.oret.2023.10.003","volume":"8","author":"SD Scarboro","year":"2024","unstructured":"Scarboro SD, Harper CA 3rd, Karsaliya G et al (2024) The incidence and timing of treatment-requiring retinopathy of prematurity in nanopremature and micropremature infants in the United States: A national multicenter retrospective cohort study. Ophthalmol Retina 8(3):279\u2013287. https:\/\/doi.org\/10.1016\/j.oret.2023.10.003","journal-title":"Ophthalmol Retina"},{"issue":"15","key":"6820_CR66","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.3390\/ijms23158529","volume":"23","author":"J Ryu","year":"2022","unstructured":"Ryu J (2022) New aspects on the treatment of retinopathy of prematurity: Currently available therapies and emerging novel therapeutics. Int J Mol Sci 23(15):8529. https:\/\/doi.org\/10.3390\/ijms23158529","journal-title":"Int J Mol Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06820-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:45:31Z","timestamp":1757137531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06820-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6820"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06820-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors, informed consent is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and inform consent"}}]}}